Study on mechanism of Yourenji Capsules in improving osteoporosis based on network pharmacology and proteomics.
10.19540/j.cnki.cjcmm.20241017.201
- Author:
Yun-Hang GAO
1
;
Han LI
1
;
Jian-Liang LI
1
;
Ling SONG
1
;
Teng-Fei CHEN
1
;
Hong-Ping HOU
1
;
Bo PENG
1
;
Peng LI
2
;
Guang-Ping ZHANG
1
Author Information
1. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Hebei Yuzhilin Biotechnology Co., Ltd. Shijiazhuang 050000, China.
- Publication Type:Journal Article
- Keywords:
Yourenji Capsules;
network pharmacology;
osteoporosis;
ovariectomy model;
proteomics
- MeSH:
Animals;
Drugs, Chinese Herbal/administration & dosage*;
Osteoporosis/metabolism*;
Proteomics;
Rats;
Rats, Sprague-Dawley;
Network Pharmacology;
Female;
Protein Interaction Maps/drug effects*;
Capsules;
Humans;
Signal Transduction/drug effects*
- From:
China Journal of Chinese Materia Medica
2025;50(2):515-526
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to explore the pharmacological mechanism of Yourenji Capsules(YRJ) in improving osteoporosis by combining network pharmacology and proteomics technologies. The SD rats were randomly divided into a blank control group and a 700 mg·kg~(-1) YRJ group. The rats were subjected to gavage administration with the corresponding drugs, and the blank serum, drug-containing serum, and YRJ samples were compared using ultra performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry(UPLC-Q-TOF-MS/MS) to analyze the main components absorbed into blood. Network pharmacology analysis was conducted based on the YRJ components absorbed into blood to obtain related targets of the components and target genes involved in osteoporosis, and Venn diagrams were used to identify the intersection of drug action targets and disease targets. The STRING database was used for protein-protein interaction(PPI) network analysis of potential target proteins to construct a PPI network. Gene Ontology(GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment were performed using Enrichr to investigate the potential mechanism of action of YRJ. Ovariectomy(OVX) was performed to establish a rat model of osteoporosis, and the rats were divided into a sham group, a model group, and a 700 mg·kg~(-1) YRJ group. The rats were given the corresponding drugs by gavage. The femurs of the rats were subjected to label-free proteomics analysis to detect differentially expressed proteins, and GO functional enrichment and KEGG pathway enrichment analyses were performed on the differentially expressed proteins. With the help of network pharmacology and proteomics results, the mechanism by which YRJ improves osteoporosis was predicted. The analysis of the YRJ components absorbed into blood revealed 23 bioactive components of YRJ, and network pharmacology results indicated that key targets involved include tumor necrosis factor(TNF), tumor protein p53(TP53), protein kinase(AKT1), and matrix metalloproteinase 9(MMP9). These targets are mainly involved in osteoclast differentiation, estrogen signaling pathways, and nuclear factor-kappa B(NF-κB) signaling pathways. Additionally, the proteomics analysis highlighted important pathways such as peroxisome proliferator-activated receptor(PPAR) signaling pathways, mitogen-activated protein kinase(MAPK) signaling pathways, and β-alanine metabolism. The combined approaches of network pharmacology and proteomics have revealed that the mechanism by which YRJ improves osteoporosis may be closely related to the regulation of inflammation, osteoblast, and osteoclast metabolic pathways. The main pathways involved include the NF-κB signaling pathways, MAPK signaling pathways, and PPAR signaling pathways, among others.
